Gen-Probe Acquires GTI Diagnostics for $53 Million in Cash


Gen-Probe (Nasdaq: GPRO), a maker of disease diagnosis products based in San Diego, announced today that it has acquired privately-held GTI Diagnostics for $53 million in cash.

GTI produces a number of immune system-related testing products, including ones that measure a patient's immune response to therapies for bleeding disorders.  Wisconsin-based GTI also produces the white blood cell detection products sold by Gen-Probe under the Lifecodes brand. 

"Acquiring GTI enables us to broaden and strengthen our transplant diagnostics business," said Carl Hull, Gen-Probe's CEO.

"In addition, the acquisition gives us access to growing coagulation and transfusion-related blood bank products that we can sell to our current customer base."

Excluding acquisition charges, which have not yet been estimated, Gen-Probe said it expects the deal to be slightly accretive to its 2011 earnings per share. 

The deal was financed by the cash Gen-Probe had on hand. As of September 30, the company had about $149 million of cash. 

Gen-Probe’s shares have edged up by 0.5% to trade at $57.86 as of 11:33 am EST.

Quick facts: Gen-Probe

Price: 4.87 USD

Market: NASDAQ
Market Cap: $768.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Arcadia Biosciences reports strong 2Q revenue despite coronavirus impact

Arcadia Biosciences Inc (NASDAQ:RKDA) CEO Matthew Plavan tells Proactive the California-based group's 2Q revenue growth was fueled by GLA sales and GoodWheat royalties. Plavan says the company also cinched a trio of recent GoodWheat agreements: a collaboration with Corner Foods to bring its...

6 hours, 50 minutes ago

2 min read